Volume Alert - SAN 8.37 Banco Santander $SAN Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - SAN 8.37 Banco Santander $SAN Hit a high today of 8.52 Closing the day 11/06/14 at 8.37 -0.10 -1.18% With a day low of 8.26 and a total volume of 12,460,698.

SAN Recent Posts: http://investorshangout.com/Banco-Santander-S...SAN-52719/

SAN Banco Santander Recent Headline News

Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Business Wire - Tue Nov 04, 5:00AM CST
Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

Banco Santander Brasil (BSBR) Stock Continues to Sink After Share Buyout
at The Street - Mon Nov 03, 10:03AM CST
Banco Santander Brasil (BSBR) stock continues to tumble after its parent company raised its stake in the Brazilian unit to 88.3% last Friday.
SAN: 8.37 (-0.10), BSBR: 5.56 (+0.06)

Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
PR Newswire - Mon Nov 03, 7:30AM CST
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu" compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

Conference Participation, Dividend, Upcoming Annual Meeting, Training Program, and Promotional Event - Research Reports on Santander Brasil, Goldman Sachs, Visa, Banco Santander and American Express
PR Newswire - Thu Oct 30, 7:30AM CDT
Today, Analysts Review released its research reports regarding Banco Santander Brasil SA (NYSE: BSBR), The Goldman Sachs Group Inc. (NYSE: GS), Visa Inc. (NYSE: V), Banco Santander, S.A. (NYSE: SAN) and American Express Company (NYSE: AXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7556-100free.
SAN: 8.37 (-0.10), V: 250.09 (+0.56), GS: 191.00 (+1.16), AXP: 91.58 (-0.84), BSBR: 5.56 (+0.06)

Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
PR Newswire - Tue Oct 28, 7:34AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
PR Newswire - Tue Oct 28, 5:00AM CDT
The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development. The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

Sanofi Q3 2014 Results - Interview with Jérôme Contamine
PR Newswire - Tue Oct 28, 2:00AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and full year guidance.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

SmarTrend Watching for Potential Rebound in Shares of Banco Santander After 2.58% Loss
Comtex SmarTrend(R) - Mon Oct 27, 4:08PM CDT
Banco Santander (NYSE:SAN) traded in a range yesterday that spanned from a low of $8.51 to a high of $8.72. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $8.67 on volume of 38.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SAN: 8.37 (-0.10)

80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 15.01 (-0.17), SAN: 8.37 (-0.10), HSBC: 50.36 (-0.14), DB: 30.62 (-0.30), NBG: 2.43 (-0.13), RBS: 12.06 (-0.22), LYG: 4.82 (-0.09)

Review on Diversified Banks Stocks - US Bancorp, Banco Santander Brasil, Banco Santander, National Bank of Greece, and Comerica
PR Newswire - Fri Oct 24, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: US Bancorp (NYSE: USB), Banco Santander Brasil S.A. (NYSE: BSBR), Banco Santander S.A. (NYSE: SAN), National Bank of Greece S.A. (NYSE: NBG), and Comerica Inc. (NYSE: CMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Financials Sector Index ended the day at 308.34, up 0.98%, with the index advancing 4.62% on YTD basis. Register for your complimentary reports on these five stocks at:
SAN: 8.37 (-0.10), USB: 43.92 (+0.40), NBG: 2.43 (-0.13), CMA: 48.90 (+0.61), BSBR: 5.56 (+0.06)

Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
PR Newswire - Wed Oct 22, 9:54AM CDT
Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., announced today that its Board of Directors declared a dividend on SHUSA's Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on November 17, 2014 to holders of record on November 1, 2014 for SHUSA's Series C Non-Cumulative Perpetual Preferred Stock (NYSE: SOVPRC).
SAN: 8.37 (-0.10)

Results from Two Phase III Studies Added to U.S. Label of Genzyme's Aubagio
Business Wire - Mon Oct 20, 9:35AM CDT
Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio(R) (teriflunomide) in the product's U.S. label.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
Business Wire - Mon Oct 20, 7:01AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies' investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB(1), has been accepted for review by the U.S. Food and Drug Administration (FDA). If approved, it would be the first pediatric combination vaccine in the United States designed to help protect against six important diseases - diphtheria, tetanus, pertussis (whooping cough), polio (poliovirus types 1, 2, and 3), invasive disease caused by Haemophilus influenzae type b (Hib), and hepatitis B.
SAN: 8.37 (-0.10), MRK: 59.26 (-0.31), SNY: 45.86 (+0.16)

Regeneron Pharmaceuticals begins Phase 3 clinical study of dupilumab in adults patients with moderate-to-severe atopic dermatitis
M2 - Mon Oct 20, 6:53AM CDT
Biopharmaceutical company Regeneron Pharmaceuticals (NasdaqGS :REGN) said on Monday that it has dosed the first patients in a Phase 3 clinical study of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications in partnership with Sanofi (EURONEXT:SAN)(NYSE:SNY) .
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16), REGN: 376.94 (+8.43)

Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
PR Newswire - Mon Oct 20, 6:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16), REGN: 376.94 (+8.43)

Homeownership Programs, New Apps for Mortgage and Real Estate Professionals, Dividend, and Market Activity - Research Reports on Radian, Banco Santander, BioMed Realty, Chimera and Genworth
PR Newswire - Fri Oct 17, 7:35AM CDT
Today, Analysts Review released its research reports regarding Radian Group Inc. (NYSE: RDN), Banco Santander, S.A. (NYSE: SAN), BioMed Realty Trust Inc. (NYSE: BMR), Chimera Investment Corporation (NYSE: CIM) and Genworth Financial, Inc. (NYSE: GNW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7255-100free.
SAN: 8.37 (-0.10), BMR: 21.42 (-0.15), RDN: 16.39 (+0.02), CIM: 3.13 (-0.02), GNW: 8.66 (-5.41)

Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
GlobeNewswire - Thu Oct 16, 7:19AM CDT
Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it has entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN) and (NYSE:SNY).
IMDZ: 30.09 (+0.01), SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

New Survey Finds Differences In Attitudes About Diabetes Based On Age
PR Newswire - Wed Oct 15, 7:00AM CDT
Sanofi US announced today the findings of a new survey that reveals striking differences in opinion among various age groups about diabetes and available treatment options. In particular, the generation known as "millennials" (those aged 18 to 34) shows an uneasy mix of fear and ability to handle managing their diabetes, which is being diagnosed at a rate of 1.7 million new cases every year1.
SAN: 8.37 (-0.10), SNY: 45.86 (+0.16)

1 Bank Stock to Avoid at All Costs
Motley Fool Staff - Motley Fool - Mon Oct 13, 11:35AM CDT
There are certainly some bargains to be had in the banking sector, with many companies trading at historically low valuations and growing their operations very rapidly. However, some stocks might appear to be better investments than they actually...
SAN: 8.37 (-0.10), NYCB: 15.84 (+0.14), BAC: 17.36 (+0.02), FBP: 5.25 (+0.03), MCO: 98.99 (-0.38)

Downgrade Alert for Banco Santander (SAN)
Comtex SmarTrend(R) - Tue Oct 07, 8:00AM CDT
Banco Santander (NYSE:SAN) was downgraded from Neutral to Reduce at Nomura today. The stock closed yesterday at $9.33 on volume of 7.0 million shares, below average daily volume of 7.0 million. Banco Santander Chile attracts deposits and offers retail and commercial banking services in Chile. The Bank offers personal and corporate loans, credit cards, mutual funds, lease financing, securities brokerage services, and business consulting.
SAN: 8.37 (-0.10)

Banco Santander S.A. (SAN) Stock Research Links

SAN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 205

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 135

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 181

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 22

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 178

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading

Top 5 Most Recently Viewed Articles

Streamlined Shipping Solutions for UK Businesses by Wix.com

Updated Category News Views 279

Enhancing Shipping for UK Businesses with Wix.com Wix.com Ltd. (NASDAQ: WIX) has taken a significant step forward in supporting UK businesses by integrating Royal Mail within its innovative Wix Shipping platform. This breakthrough means that merchants can now easily transition from traditional, manual shipping processes to a fully automated system, streamlining their...

Continue Reading
FullFlex.Agency Innovation: AI Solutions for Business Growth

Updated Category News Views 147

FullFlex.Agency Unleashes Innovative Marketing Solutions FullFlex.Agency is celebrating its continued success as it enters the fourth quarter of its second year. This dynamic organization, known for its robust AI-powered marketing solutions and transparent pricing structures, emphasizes its commitment to helping businesses thrive across various sectors. Expansion of...

Continue Reading
NexBank Achieves Recognition as Leading Mortgage Lender

Updated Category News Views 207

NexBank: A Consistent Leader in Mortgage Lending NexBank has once again made headlines by being recognized as one of the top mortgage lenders in the nation for the fourth consecutive year. This achievement underscores the bank's ongoing commitment to excellence in the mortgage industry. The latest rankings show that NexBank secured the 12th position for Correspondent...

Continue Reading
First Mining Gold Corp. Strengthens Position with First Majestic

Updated Category News Views 173

Key Agreement Enhancements Between First Mining Gold and First Majestic First Mining Gold Corp. (TSX: FF) has announced an important agreement with First Majestic Silver Corp. that is expected to positively impact its financial position and operational strategy. This mutually beneficial arrangement revises the parameters of the existing silver purchase agreement,...

Continue Reading
Expert Weighs In: College Apps Need Strategy, Not Count

Updated Category News Views 38

A Lesson for College-Bound Families When the question comes up about college applications, you expect to hear numbers thrown around like eight, twelve, or even twenty. But the idea that there's some magic number to crack the admissions code? It just doesn't hold water. Instead, it's all about the risk baked into your list of schools. That's where HelloCollege's recent...

Continue Reading